MRSN - Mersana Therapeutics, Inc.

29.08
0.040   0.138%

Share volume: 712,460
Last Updated: 01-05-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$29.04
0.04
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 25%
Dept financing 7%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
216.43%
1 Year
7,634.04%
2 Year
823.17%
Key data
Stock price
$29.08
P/E Ratio 
0.00
DAY RANGE
$28.78 - $30.39
EPS 
-$6.68
52 WEEK RANGE
$0.27 - $30.39
52 WEEK CHANGE
$7,356.41
MARKET CAP 
38.728 M
YIELD 
N/A
SHARES OUTSTANDING 
4.999 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
4.74
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Anna Protopapas
Region: US
Website: mersana.com
Employees: 150
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Mersana Therapeutics, Inc. develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for ovarian cancer and NSCLC adenocarcinoma.

Recent news